Did Pfizer Do Any Safety Studies? Part 3: Pharmacokinetics

This is the 3rd installment of discussion about Pfizer Non-Clinical Studies used by FDA to approve the product. We are focusing on Pharmacokinetics, a branch of science studying the distribution of drugs/biologics through the body, the metabolism and clearance and the implications for product safety. Some important relevant material about what Pfizer knew about risks of adverse events at the time of clinical trials can be found here: https://www.icandecide.org/ican_press/pfizers-own-informed-consent-documents-undermine-fda-and-cdcs-cries-of-safe-and-effective/

Correction: there are 2 versions of the product, V8 and V9 mentioned in the package of documents. Pfizer states that V9 is the final vaccine candidate. Specifically that it is BNT162b2 (V9). I am still investigating the issue of multiple versions of products being included in various stages of development. For example, I already found that in the Phase I/II human clinical trial Pfizer used BNT162b1 (not BNT162b2 as they claim being final vaccine candidate). This is extremely concerning and not allowed practice under the same IND (Investigational New Drug) application.